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Background/purpose: NGX-4010 (QUTENZA™; NeurogesX Inc, San Mateo, CA), a capsaicin 
8% dermal patch, is licensed in the European Union for the treatment of peripheral neuropathic 
pain (PNP) in nondiabetic adults and in the United States for the treatment of neuropathic pain 
associated with postherpetic neuralgia (PHN). While NGX-4010 treatment is associated with 
a low risk of systemic adverse events, patch application-related pain is common and may be 
managed with local cooling and/or oral analgesics. This article characterizes the tolerability of 
NGX-4010 and will help to guide any pain management.
Methods: This integrated analysis of tolerability data collected from the NGX-4010 clinical 
study program included 1696 patients with PNP. Patch application-related pain on the treatment 
day was captured as Numeric Pain Rating Scale (NPRS) “pain now” scores while “average 
pain for the past 24 hours” NPRS scores were analyzed for 7 days following treatment. Other 
tolerability assessments included the percentage of patients completing $90% of the intended 
treatment duration and patients using medication for patch application-related pain.
Results: The mean maximum change in “pain now” NPRS scores from pretreatment levels 
during and after patch application was 2.6 for all patients. This pain was transient and resolved 
following patch removal. Mean “average pain for the past 24 hours” NPRS scores returned to 
baseline by the evening of the treatment day for patients with PHN, and the evening of day 2 
for patients with human immunodeficiency virus-associated distal sensory polyneuropathy 
or painful diabetic neuropathy. Repeated NGX-4010 applications did not affect the intensity 
of patch application-related pain. Almost all patients ($98%) completed $90% of the full 
treatment duration, regardless of the number of treatments received.
Conclusion: Transient patch application-related pain with NGX-4010 can be managed with local 
cooling and/or oral analgesics in nearly all cases. Patient adherence to the full intended treatment 
duration indicated that patch application-related pain was not a barrier to NGX-4010 use.
Keywords: capsaicin 8% patch, NGX-4010, patch application-related pain, neuropathic pain
Introduction
Peripheral neuropathic pain (PNP) conditions, such as postherpetic neuralgia (PHN) and 
human immunodeficiency virus-associated distal sensory polyneuropathy (HIV-DSP), 
exert a heavy burden of illness on affected patients.1,2 Conditions such as HIV-DSP are 
particularly difficult to treat, and most available systemic therapies for PNP provide 
fewer than half of patients with meaningful pain relief.3,4
The transient receptor potential vanilloid 1 (TRPV1) receptor is highly expressed on 
peripheral nociceptors and is a key modulator of pain transmission.5 Altered nociceptor 
expression of TRPV1 may play a role in PNP,6–8 and makes this receptor a logical target Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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for treating such pain. Capsaicin is a selective agonist of the 
TRPV1 receptor5;the initial exposure of these receptors to 
high capsaicin concentrations causes nociceptor excitation 
and consequently pain, perceived as a hot, burning   sensation. 
However, prolonged stimulation with capsaicin causes a 
reversible defunctionalization and reduction of the nerve 
fibers in the epidermis, and results in the inhibition of pain 
transmission.9–11 NGX-4010 (QUTENZA™; NeurogesX Inc, 
San Mateo, CA) is a capsaicin 8% patch designed to rapidly 
deliver capsaicin to peripheral nociceptors. In the European 
Union (EU), NGX-4010 is approved for the treatment of PNP 
in nondiabetic adults either alone or in combination with 
other neuropathic pain (NP) medications. It is also approved 
by the United States (US) Food and Drug Administration for 
the treatment of NP associated with PHN. Before application 
of NGX-4010, the skin is pretreated with topical anesthetic 
to reduce capsaicin-induced discomfort. Up to four patches, 
designed for cutting to the treatment area size and shape, can 
be applied for 60 minutes (US indication) or 30 minutes to 
the feet and 60 minutes to any other area (EU indication), 
excluding the face, scalp, and mucous membranes.
Single NGX-4010 applications have resulted in rapid, 
prolonged (up to 12 weeks) pain reductions in randomized, 
controlled, clinical studies of patients with PHN and HIV-
DSP.12–16 Moreover, both single and repeated NGX-4010 
applications were well tolerated.12–17 Apart from transient 
increases in blood pressure, likely associated with the pain 
experienced during the application procedure, NGX-4010 
was not associated with systemic adverse events. This is 
as expected, since there is minimal systemic absorption 
of capsaicin.18 Application-site adverse events, such as 
patch application-related pain and erythema, were the most 
commonly reported adverse events. Although generally mild 
or moderate in severity and transient, patch application-
related pain needs adequate management during clinical 
practice. As NGX-4010 moves from clinical trials into 
clinical practice, clinicians have raised questions about the 
degree of patch application-related pain, and it has been 
suggested that epidural injections or intravenous opioids 
be used pre- and post-NGX-4010 application.19 However, 
neither intervention was routinely required in the clinical 
trials; patch application-related pain was treated with oral 
analgesics (eg, short-acting opioids) during and following 
NGX-4010 application and/or local cooling (eg, cold packs) 
after patch removal.
This manuscript describes integrated data analyzing 
patch application-related pain experienced by patients with 
PHN, HIV-DSP, or PDN who were treated with NGX-4010 
during the clinical study program, and the measures taken 
to alleviate this pain.
Methods
Patients
Safety and tolerability data from 12 studies of NGX-4010 
that included patients with PNP due to PHN, HIV-DSP, 
or PDN were integrated and analyzed. The Clinical  Trials.
gov identifiers of the registered trials, along with the 
dates of first registration, are as follows: NCT00034710 
(May 1, 2002), NCT00061776 (June 3, 2003), NCT00068081 
(September 5, 2003), NCT00115310 (June 21, 2005), 
NCT00300222 (March 6, 2006), NCT00061152 (May 21, 
2003), NCT00064623 (July 10, 2003), NCT00085761 (June 
14, 2004), NCT00321672 (May 2, 2006), NCT00082316 
(May 5, 2004), and NCT00233155 (October 3, 2005).
Eight of the studies were randomized, controlled studies 
or contained a randomized, controlled period, three were 
open-label, uncontrolled studies, and one was an open-
label, uncontrolled extension study. Patients were recruited 
directly by the study centers from their existing patient 
database, or through print advertising, or radio, or television 
advertisements. Enrolled patients had an average Numeric 
Pain Rating Scale (NPRS) score20 of 3–9 (3–8 in two studies). 
Patients with PHN were eligible if at least 6 months had 
elapsed since shingle vesicle crusting (at least 3 months 
in two studies). Patients with PDN had to have NP for at 
least 3 months and patients with HIV-DSP had to be at least 
2 months from diagnosis (3 months in one study).
Patients taking chronic analgesics had to be on a stable 
dose of those medications for at least 21 days before the day 
of study-patch application and throughout the study period. 
Exclusion and inclusion criteria were similar between studies, 
as described previously.12–15
Studies were approved by Institutional Review Boards 
and/or independent Ethics Committees at all participating 
sites, and conducted in accordance with the ethical principles 
of the Declaration of Helsinki, Good Clinical Practice 
guidelines, and applicable regulatory requirements. Written 
informed consent was obtained from all participating patients 
before initiating study-related procedures.
Procedures
Studies included a baseline screening period of 7–14 days 
followed by a treatment day (day 0), and a 12-week 
post-treatment assessment period (4 weeks in one study) 
with periodic clinic visits. In the randomized, controlled 
studies, patients were randomized to NGX-4010 (capsaicin Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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640 µg/cm2, 8% w/w) or a control patch that was identically 
formulated, but contained a lower capsaicin concentration 
(3.2 µg/cm2, 0.04% w/w). The low-concentration capsaicin 
control patches were used in place of placebo patches to 
  provide effective blinding in the studies, since topical capsai-
cin can produce local erythema and a burning sensation. The 
treatment assigned to individual patients was determined by 
a randomization scheme prepared by Fisher Clinical Services 
(Allentown, PA) or Cardinal Health (Morrisville, NC). In the 
uncontrolled extension studies or the extension phase of the 
double-blind studies, patients were allowed to receive open-
label 60-minute NGX-4010 treatments at least 12 weeks apart 
(6 weeks in the extension study to NCT00034710).
All patients were pretreated with a topical anes-
thetic (lidocaine 4%; ELA-Max4® or LMX4® [Ferndale 
  Laboratories, Inc, Ferndale, MI]; Topicaine® Gel [ESBA 
Laboratories, Inc, Jupiter, FL] or Betacaine® Enhanced Gel 4 
[Theraderm, Inc, Tampa, FL]) for 60 minutes. After removal 
of the topical anesthetic, the treatment area was washed 
with soap and water and thoroughly dried, and NGX-4010 
patches were applied for 30, 60, or 90 minutes directly to 
the painful area(s) (up to 1120 cm2), depending on the study 
protocol. After patch removal, the area was cleansed with 
a proprietary cleansing gel formulated to remove residual 
capsaicin. Patients were monitored for 2 hours (4 hours in 
one study) after patch removal.   Oxycodone oral solution 
(1 mg/mL) or a similar oral opioid analgesic could be 
administered at the onset of patch application-related pain 
and as needed thereafter in the clinic. After patch removal, 
local cooling (eg, cold packs) could also be used to relieve 
patch application-related pain. Patients could also take 
short-acting opioid medication (hydrocodone bitartrate 
5 mg/acetaminophen 500 mg) for up to 3–7 days (depending 
on the study) after patch application for patch application-
related pain, as needed.
Assessments and analyses
Tolerability assessments included pain assessment before, 
during, and after the treatment procedure using NPRS 
scores for “pain now.” The mean absolute change in “pain 
now” NPRS score from the pretreatment time point to 
  several   post-treatment time points on the treatment day 
were   calculated. In addition, the mean maximum change in 
“pain now” NPRS score on the treatment day, the number 
and   percentage of patients completing $90% of the patch 
  application duration, and the number and percentage of 
patients who reported an increase in NPRS score of .2 were 
calculated and subgroup analyses performed,   comparing 
patients who were or were not taking concomitant NP 
  medication (defined as anticonvulsants, nonselective-
serotonin reuptake inhibitor antidepressants, or opioids at 
day -1 for at least 7 consecutive days). The percentage of 
patients using medication for patch application-related pain 
was also determined.20 Mean absolute changes in “average 
pain for the past 24 hours” NPRS score from baseline for 
the 7 days following NGX-4010 application were calculated 
from the daily “average pain for the past 24 hours” NPRS 
scores captured at 21:00 hours every evening in a paper diary 
throughout the study period.
Results
Demographics
Demographic and baseline characteristics of the 1696 patients 
who received NGX-4010 are shown by indication in Table 1. 
The majority of patients had PHN (54%) and patients with 
HIV-DSP and PDN comprised 40% and 5% of the population, 
respectively. Approximately 75% of patients received a 
single treatment, 20% received two or three treatments, and 
approximately 5% received four treatments. No patients with 
PDN were treated more than once. The mean treatment area 
size was 620 cm2; patients with HIV-DSP or PDN tended 
to have larger mean treatment areas (935 cm2 and 989 cm2, 
respectively) than patients with PHN (349 cm2). The average 
baseline pain level was 5.8 and was comparable for each 
indication. About half of PHN or PDN patients and 69% of 
HIV-DSP patients were taking concomitant NP medication 
(defined as anticonvulsants, nonselective-serotonin reuptake 
inhibitor antidepressants, or opioids) at study entry and dur-
ing the studies.
nPRs scores during and after ngX-4010 
application
Mean “pain now” NPRS scores on the day of treatment 
are shown by indication in Figure 1A. In all cohorts, 
pain decreased during topical anesthetic application 
and increased during and after NGX-4010 application. 
Patients with PHN showed a mean maximum change in 
NPRS score of 2.8 and patients with HIV-DSP or PDN 
showed a mean maximum change of 2.3 (Table 2). For 
all patients, a maximum change in NPRS score of 2.6 was 
observed during patch application and up to 85 minutes 
post-treatment. In addition, 48% of patients reported an 
increase in NPRS score of .2 points during and after 
patch application, including the evening of the treatment 
day. Subgroup analyses comparing patients who were or 
were not taking concomitant NP medication revealed no Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Table 1 Demographic and baseline characteristics by indication
Characteristics NGX-4010
PHN  
(n = 920)
HIV-DSP  
(n = 685)
PDN  
(n = 91)
Total  
(n = 1696)
Age (years) on day of first treatment
  Mean (sD) 71 (11) 49 (8) 59 (11) 61 (15)
  Minimum, maximum 21, 94 22, 74 37, 79 21, 94
 $ 65, n (%) 693 (75) 26 (4) 28 (31) 747 (44)
 $ 75, n (%) 389 (42) 0 8 (9) 397 (23)
sex
  Male, n (%) 432 (47) 616 (90) 52 (57) 1100 (65)
Race
  Asian, n (%) 15 (2) 5 (1) 1 (1) 21 (1)
  Black, n (%) 27 (3) 187 (27) 10 (11) 224 (13)
  caucasian, n (%) 826 (90) 424 (62) 67 (74) 1317 (78)
  Other, n (%) 52 (6) 69 (10) 13 (14) 134 (8)
Treatment area (cm2)
  Mean (sD) 349 (231) 935 (249) 989 (200) 620 (378)
Duration of pain (years)
  Mean (sD) 3.5 (4.1) 5.7 (3.8) 5.0 (4.7) 4.5 (4.1)
Baseline nPRs score for “average pain for the past 24 hours”a
  Mean (sD) 5.6 (1.6) 6.0 (1.6) 5.8 (1.4) 5.8 (1.6)
On concomitant neuropathic pain medication,b n (%)
  Yes 481 (52) 472 (69) 46 (51) 999 (59)
    Opioids only 84 (9) 64 (9) 4 (4) 152 (9)
    Anticonvulsants only 168 (18) 128 (19) 19 (21) 315 (19)
    non-ssRi antidepressant only 57 (6) 66 (10) 8 (9) 131 (8)
    Opioids and anticonvulsants 85 (9) 64 (9) 7 (8) 156 (9)
    Opioids and non-ssRi antidepressants 13 (1) 23 (3) 3 (3) 39 (2)
    Anticonvulsants and non-ssRi antidepressants 46 (5) 81 (12) 3 (3) 130 (8)
    All three 28 (3) 46 (7) 2 (2) 76 (4)
number of treatments received, n (%)
  One 691 (75) 485 (71) 91 (100) 1267 (75)
  Two 100 (11) 76 (11) 0 176 (10)
  Three 85 (9) 75 (11) 0 160 (9)
  Four 44 (5) 49 (7) 0 93 (5)
Notes: aBaseline nPRs scores for “average pain for the past 24 hours” were recorded in the evening (at 21:00 hours), beginning on the day of the screening visit (usually 
day–14) to day–1, as part of diary completion prior to study drug treatment; bpatient is defined as being on concomitant pain medication if he/she is on an anticonvulsant, 
nonselective-ssRi antidepressant, or opioid that was used on day–1 and was taken for a total duration of at least 7 consecutive days.
Abbreviations: non-SSRI, nonselective-serotonin reuptake inhibitor; HIV-DSP, human immunodeficiency virus-distal sensory polyneuropathy; NPRS, Numeric Pain Rating 
scale; PDn, painful diabetic neuropathy; Phn, postherpetic neuralgia; sD, standard deviation.
difference in the tolerability of NGX-4010 on the treatment 
day (data not shown). NPRS score increases were transient 
and returned, on average, to baseline within 85 minutes 
following treatment (Figure 1A).
Mean “average pain for the past 24 hours” NPRS scores 
for patients with PHN returned to baseline by the evening of 
the treatment day, decreased below baseline on day 1, and 
continued to fall below baseline on days 2–7 following treat-
ment (Figure 1B). In patients with HIV-DSP or PDN, mean 
“average pain for the past 24 hours” NPRS scores returned to 
baseline by the evening of day 2, indicating a slightly longer 
duration of patch application-related pain in patients with 
these conditions. By day 3, patients in all cohorts had less 
pain, on average, than at baseline. There was no evidence of 
a return of patch application-related pain after day 0 in any 
patient population (Figure 1B).
Medications for patch application-related 
pain and patient compliance
Medications required for patch application-related pain were 
used by 55% of patients treated with NGX-4010 (Table 2). 
A higher percentage of patients with HIV-DSP compared 
with the other two cohorts reported using such medications. 
Medications were most commonly used on the treatment day 
and use decreased considerably by day 5.
Nearly all patients (99%) were able to tolerate NGX-4010 
treatment to complete $90% of the full treatment duration 
(Table 2).Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Tolerability following repeated  
ngX-4010 applications
With repeated applications of NGX-4010 (Table 3) the 
maximum change in NPRS scores during and after NGX-
4010 application remained the same or slightly decreased 
in patients with PHN or HIV-DSP. The number of patients 
who reported an increase in NPRS score of .2 also remained 
stable with repeated applications (Table 3).
Patient compliance was not affected by repeated appli-
cations; nearly all patients completed $90% of the full 
Table 2 summary of tolerability on the day of treatment by indication
NGX-4010
PHN  
(n = 919)
HIV-DSP  
(n = 685)
PDN  
(n = 91)
Total  
(n = 1696)
Maximum change in nPRs scorea during topical anesthetic application, mean (sD) -1.6 (2.0) -1.0 (1.6) -1.4 (1.8) -1.3 (1.8)
Maximum change in nPRs scorea during and after patch application,b mean (sD) 2.8 (2.7) 2.3 (2.7) 2.3 (3.1) 2.6 (2.7)
subjects with an increase in nPRs score of .2 points on day 0,b n (%) 477 (52) 299 (44) 42 (46) 818 (48)
subjects completing at least 90% of the intended patch application duration, n (%) 901 (98) 681 (99) 91 (100) 1673 (99)
subjects using medication for treatment-related pain on days 0–5, n (%) 451 (49) 460 (67) 13 (14) 924 (55)
Notes: achange from preanesthetic time point; bincludes the evening of the treatment day.
Abbreviations:  HIV-DSP,  human  immunodeficiency  virus-distal  sensory  polyneuropathy;  NPRS,  Numeric  Pain  Rating  Scale;  PDN,  painful  diabetic  neuropathy; 
Phn, postherpetic neuralgia; sD, standard deviation.
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Figure 1 Mean (± standard error) “pain now” numeric Pain Rating scale (nPRs) score change from the pretreatment time point during and immediately following the 
application procedure on the treatment day (A) and mean (± standard error) “average pain for the past 24 hours” nPRs score change from baseline on days 0 to 7 (B) for 
each indication. 
Abbreviations: HIV-DSP, human immunodeficiency virus-distal sensory polyneuropathy; PDN, painful diabetic neuropathy; PHN, postherpetic neuralgia.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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retreatment duration, regardless of the number of treatments 
received (Table 3). The percentage of patients using 
medication for patch application-related pain on days 0–5 
also remained the same or slightly decreased with repeated 
NGX-4010 applications.
Discussion
Analyses of the tolerability data from the NGX-4010 clinical 
study program demonstrate that patch application-related 
pain increases were transient and generally began to resolve 
following removal of NGX-4010. Interestingly, despite the 
fact that the patch application-related pain increase during 
and shortly after patch application was higher in patients with 
PHN, the average pain score in the PHN cohort returned to 
baseline on the day of treatment, whereas in the PDN and 
HIV-DSP cohorts pain scores declined more gradually. These 
results appear to indicate a slower rate of pain decrease after 
the treatment procedure in patients with HIV-DSP or PDN 
than in those with PHN. These differences may be due to the 
difference in skin thickness between the trunk (PHN) and the 
feet (HIV-DSP or PDN). This study also found that repeated 
applications of NGX-4010 did not affect patch application-
related pain and tolerability.
During the clinical studies, patch application-related 
pain was treated with oxycodone oral solution (1 mg/mL) 
as needed in the clinic on the day of treatment. Patients 
could also take short-acting opioid medication (hydrocodone 
bitartrate 5 mg/acetaminophen 500 mg) for up to 3–7 days 
(depending on the study) after patch application for patch 
application-related pain, as needed. Just over half of all 
patients in the NGX-4010 clinical trials used medication 
for patch application-related pain, with most medication 
used on the treatment day and decreasing rapidly thereafter. 
  Previous NGX-4010 reports have shown oxycodone use on 
the treatment day to be 10.6–17.1 mg in patients with PHN 
and 12.3–31.7 mg in patients with HIV-DSP.15,17,21 While 
design of the NGX-4010 clinical trials mandated that medica-
tion for patch application-related pain could not be admin-
istered until after its onset, future studies to investigate the 
usefulness of preemptive analgesia with oral opioids or other 
oral analgesics (eg, nonsteroidal anti-inflammatory drugs, 
aspirin) as an alternative to topical anesthetic pretreatment 
could be considered. It is important to note that the use of 
concomitant NP medications did not have an effect on patch 
application-related pain.
During the clinical trials, cooling measures such as 
sealed cool gel packs, gauze misted with cool water, or 
fans were applied to the treatment area after patch removal. 
These measures were found to relieve patch application-
related pain in $90% of the patients in whom they were 
used. In the absence of capsaicin, the TRPV1 receptor is 
activated at approximately 43°C; the binding of capsaicin 
to TRPV1 is thought to lower the activation temperature 
of the receptor, allowing for activation at body temperature 
and a feeling of application-site burning.22 It is theoretically 
possible that cooling the treatment area during NGX-4010 
application may make it harder for capsaicin to activate the 
receptor, resulting in reduced efficacy. Although analysis of 
clinical study data has not shown any apparent effect of the 
use of cooling on the efficacy of NGX-4010 (data on file), 
in the clinical studies cooling measures were mostly used 
following patch removal. As only limited data exist regarding 
the use of cooling measures during the application of the 
NGX-4010 patch, it is recommended that cooling should 
Table 3 summary of tolerability on the day of treatment by indication and treatment cycle
Change from pre-LMX4® time point NGX-4010 treatment cycle
1 2 3 4
Phn 
  Maximum change in nPRs score during topical anesthetic application, mean (sD) 
  Maximum change in nPRs score during and after patch application,a mean (sD) 
  Patients with an increase in nPRs score of .2 points on day 0,a n (%) 
  Patients with at least 90% of the intended patch application duration, n (%) 
  Patients using medication for patch application-related pain on days 0–5, n (%)
n = 370 
-1.7 (2.0) 
2.6 (2.8) 
169 (46) 
364 (98) 
198 (54)
n = 229 
-1.8 (2.0) 
2.4 (2.6) 
96 (42) 
227 (99) 
107 (47)
n = 129 
-1.6 (1.9) 
2.2 (2.8) 
54 (42) 
127 (98) 
60 (47)
n = 44 
-2.1 (1.5) 
1.6 (2.7) 
17 (39) 
44 (100) 
20 (45)
hiV-DsP 
  Maximum change in nPRs score during topical anesthetic application, mean (sD) 
  Maximum change in nPRs score during and after patch application,a mean (sD) 
  Patients with an increase in nPRs score of .2 points on day 0,a n (%) 
  Patients with at least 90% of the intended patch application duration, n (%) 
  Patients using medication for patch application-related pain on days 0–5, n (%)
n = 337 
-1.1 (1.6) 
2.3 (2.8) 
120 (36) 
333 (99) 
216 (64)
n = 200 
-1.2 (1.6) 
1.9 (2.4) 
66 (33) 
199 (100) 
125 (63)
n = 124 
-1.1 (1.3) 
1.5 (2.5) 
41 (33) 
123 (99) 
75 (60)
n = 49 
-1.3 (1.7) 
1.1 (3.0) 
18 (37) 
49 (100) 
27 (55)
Note: aincludes the evening of the treatment day.
Abbreviations: HIV-DSP, human immunodeficiency virus-distal sensory polyneuropathy; NPRS, Numeric Pain Rating Scale; PHN, postherpetic neuralgia; SD, standard 
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be applied following patch removal. If cooling is required 
during the application procedure, cool packs should only 
be applied towards the end of the procedure, in response to 
capsaicin-induced pain, and never preemptively at the start 
of the patch application. Patients should be advised that the 
treated area may be sensitive to heat, including hot showers 
and baths, direct sunlight, and vigorous exercise, for a few 
days post-treatment.
During the NGX-4010 clinical program, several measures 
were taken to alleviate and manage patch application-related 
pain. Although, other measures that might provide additional 
benefit in patients’ management were not systematically 
evaluated, psychological measures such as reassurance, 
cognitive behavioral therapy, and distraction techniques, 
which have been shown to be important in reducing pain 
sensation, might help with post-patch application-related 
pain.23–25 Therefore, in addition to treatment with a topical 
anesthetic, informing patients that they may experience patch 
application-related pain, ie, a burning sensation, that is usu-
ally temporary lasting a few hours to a few days, could have 
an impact on the patients’ ability to tolerate the pain. Further, 
reaffirming patients that the potential relief from PNP may 
last for 12 weeks13–15,26 could also help patients to tolerate 
patch application-related pain. The use of distraction tech-
niques has also been found to be useful in pain management24 
and providing patients with reading materials, a television, 
a snack, lunch, and also by staying with them, particularly 
during the last 15 minutes of treatment, may enhance the 
patients’ ability to complete treatment.
In conclusion, single and repeated NGX-4010 treatments 
are generally well tolerated and, on average, patch 
application-related pain is transient and can be satisfactorily 
controlled by oral analgesics and/or local cooling. Using 
these approaches, nearly all patients completed $90% of 
the full treatment duration, indicating that patch application-
related pain is not a barrier to adherence to the full 
intended treatment duration. The vast majority of patients 
who required intervention for treatment-related pain were 
adequately managed with simple, inexpensive approaches, 
local cooling, and/or oral medications. Aggressive pain 
control interventions such as intravenous opioids and 
epidural injections were not routinely required. Since more 
aggressive interventions do place patients at an added 
burden of physical risk and expense, the current findings 
are important as the capsaicin 8% patch begins to be used 
more commonly by health care providers. In the authors’ 
experience, patient education prior to patch application, 
reassurance, and distraction techniques are also important 
components that can assist patients in tolerating patch 
application-related pain.
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